Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Stopped early · Phase 2

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).

Key facts

Study ID

NCT02742090

Run by

TG Therapeutics, Inc.

People needed

51

Starts

2016-04-21

Expected to finish

2021-06-10

Last updated by the study team

2024-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
• Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events within prior 9 months
• Presence of measurable disease

You may not qualify if…

• Progression on prior BTK or PI3K delta inhibitor
• Prior treatment with TGR-1202
• Richter's transformation or CLL transformation to aggressive lymphoma

Where it is running

• TG Therapeutics Investigational Trial Site — Huntsville, Alabama, United States
• TG Therapeutics Investigational Trial Site — Washington D.C., District of Columbia, United States
• TG Therapeutics Investigational Trial Site — Fort Myers, Florida, United States
• TG Therapeutics Investigational Trial Site — St. Petersburg, Florida, United States
• TG Therapeutics Investigational Trial Site — Kansas City, Missouri, United States
• TG Therapeutics Investigational Trial Site — Lebanon, New Hampshire, United States
• TG Therapeutics Investigational Trial Site — Hackensack, New Jersey, United States
• TG Therapeutics Investigational Trial Site — New Hyde Park, New York, United States
• TG Therapeutics Investigational Trial Site — New York, New York, United States
• TG Therapeutics Investigational Trial Site — Rochester, New York, United States
• TG Therapeutics Investigational Trial Site — Durham, North Carolina, United States
• TG Therapeutics Investigational Trial Site — Hershey, Pennsylvania, United States
• TG Therapeutics Investigational Trial Site — Philadelphia, Pennsylvania, United States
• TG Therapeutics Investigational Trial Site — Nashville, Tennessee, United States
• TG Therapeutics Investigational Trial Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.